CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 45 enrolled
Drug / intervention
Insulin or Placebodrug
Likely dose
Insulin or Placebo 40IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00575666
NCT00575666Phase 4Completed
CompareCT.gov

Intranasal Insulin Treatment in Patients With Schizophrenia

University of Massachusetts, Worcester·interventional·Posted Dec 18, 2007·Updated Dec 17, 2012

In Brief

A Phase 4 clinical trial evaluating Insulin or Placebo for Schizophrenia. Completed, enrolled 45 participants across 1 site.

Detailed Summary

This study is an 8-week, randomized, double-blind, placebo-controlled trial of intranasal insulin as an adjunctive therapy, with a 4-week follow-up, in 60 non-diabetic schizophrenia subjects to examine insulin's effect on psychopathology and cognition. In addition, the study will examine insulin's effects on weight, food intake, resting energy expenditure, and body composition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsNational Alliance for Research on Schizophrenia and Depression, Eli Lilly and Company

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 18, 2007
Enrollment StartDec 1, 2007
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.5 years ago

Interventions

Insulin or Placebodrug

intranasal, 40IU, 4 times daily